SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Linike Medical Group Ltd (LNMG) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 48/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
75/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — LNMG
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio1.31
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.00
Book Value / Share$0.00
Revenue / Share$0.02
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2012 |
$-0.32 |
$69.3K |
$-88.35K |
-127.5% |
| 2013 |
$-0.25 |
$0.00 |
$-427.77K |
- |
| 2018 |
$0.00 |
$0.00 |
$-1.08K |
- |
| 2020 |
$0.00 |
$0.00 |
$-88.57K |
- |
| 2021 |
$0.00 |
$0.00 |
$-29.86K |
- |
| 2022 |
$0.00 |
$0.00 |
$-65.98K |
- |
| 2023 |
$0.00 |
$8.95M |
$991.04K |
11.1% |
| 2024 |
$0.00 |
$13.05M |
$-244.88K |
-1.9% |
